Abstract CT256: Results from KEYNOTE-B98: A Phase 1b/2 Study of Pembrolizumab Plus Investigational Agents in Patients with Anti-Pd-(l)1-refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Cancer Research(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined